Cargando…
Benchmarking the Covid-19 pandemic across countries and states in the USA under heterogeneous testing
Scientists and policymakers need to compare the incidence of Covid-19 across territories or periods with various levels of testing. Benchmarking based on the increase in total cases or case fatality rates is one way of comparing the evolution of the pandemic across countries or territories and could...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313551/ https://www.ncbi.nlm.nih.gov/pubmed/34312459 http://dx.doi.org/10.1038/s41598-021-94663-x |
_version_ | 1783729373198680064 |
---|---|
author | Asahi, Kenzo Undurraga, Eduardo A. Wagner, Rodrigo |
author_facet | Asahi, Kenzo Undurraga, Eduardo A. Wagner, Rodrigo |
author_sort | Asahi, Kenzo |
collection | PubMed |
description | Scientists and policymakers need to compare the incidence of Covid-19 across territories or periods with various levels of testing. Benchmarking based on the increase in total cases or case fatality rates is one way of comparing the evolution of the pandemic across countries or territories and could inform policy decisions about strategies to control coronavirus transmission. However, comparing cases and fatality rates across regions is challenging due to heterogeneity in testing and health systems. We show two complementary ways of benchmarking across territories and in time. First, we used multivariate regressions to estimate the test-elasticity of Covid-19 case incidence. Cases grow less than proportionally with testing when assessing weekly changes or looking across states in the USA. They tend to be proportional or even more than proportional when comparing the month-to-month evolution of an average country in the pandemic. Our results were robust to various model specifications. Second, we decomposed the growth in cases into test growth and positive test ratio growth to intuitively visualize the components of case growth. We hope these results can help support evidence-based decisions by public officials and help the public discussion when comparing across territories and in time. |
format | Online Article Text |
id | pubmed-8313551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-83135512021-07-27 Benchmarking the Covid-19 pandemic across countries and states in the USA under heterogeneous testing Asahi, Kenzo Undurraga, Eduardo A. Wagner, Rodrigo Sci Rep Article Scientists and policymakers need to compare the incidence of Covid-19 across territories or periods with various levels of testing. Benchmarking based on the increase in total cases or case fatality rates is one way of comparing the evolution of the pandemic across countries or territories and could inform policy decisions about strategies to control coronavirus transmission. However, comparing cases and fatality rates across regions is challenging due to heterogeneity in testing and health systems. We show two complementary ways of benchmarking across territories and in time. First, we used multivariate regressions to estimate the test-elasticity of Covid-19 case incidence. Cases grow less than proportionally with testing when assessing weekly changes or looking across states in the USA. They tend to be proportional or even more than proportional when comparing the month-to-month evolution of an average country in the pandemic. Our results were robust to various model specifications. Second, we decomposed the growth in cases into test growth and positive test ratio growth to intuitively visualize the components of case growth. We hope these results can help support evidence-based decisions by public officials and help the public discussion when comparing across territories and in time. Nature Publishing Group UK 2021-07-26 /pmc/articles/PMC8313551/ /pubmed/34312459 http://dx.doi.org/10.1038/s41598-021-94663-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Asahi, Kenzo Undurraga, Eduardo A. Wagner, Rodrigo Benchmarking the Covid-19 pandemic across countries and states in the USA under heterogeneous testing |
title | Benchmarking the Covid-19 pandemic across countries and states in the USA under heterogeneous testing |
title_full | Benchmarking the Covid-19 pandemic across countries and states in the USA under heterogeneous testing |
title_fullStr | Benchmarking the Covid-19 pandemic across countries and states in the USA under heterogeneous testing |
title_full_unstemmed | Benchmarking the Covid-19 pandemic across countries and states in the USA under heterogeneous testing |
title_short | Benchmarking the Covid-19 pandemic across countries and states in the USA under heterogeneous testing |
title_sort | benchmarking the covid-19 pandemic across countries and states in the usa under heterogeneous testing |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313551/ https://www.ncbi.nlm.nih.gov/pubmed/34312459 http://dx.doi.org/10.1038/s41598-021-94663-x |
work_keys_str_mv | AT asahikenzo benchmarkingthecovid19pandemicacrosscountriesandstatesintheusaunderheterogeneoustesting AT undurragaeduardoa benchmarkingthecovid19pandemicacrosscountriesandstatesintheusaunderheterogeneoustesting AT wagnerrodrigo benchmarkingthecovid19pandemicacrosscountriesandstatesintheusaunderheterogeneoustesting |